Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Gains from Investment Securities (2016 - 2025)

Avalo Therapeutics filings provide 10 years of Gains from Investment Securities readings, the most recent being -$510000.0 for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 89.8% to -$510000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.5 million, a 92.53% increase, with the full-year FY2024 number at -$12.5 million, changed N/A from a year prior.
  • Gains from Investment Securities hit -$510000.0 in Q4 2025 for Avalo Therapeutics, up from -$5.0 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.7 billion in Q4 2022 to a low of -$112.0 million in Q2 2024.
  • Median Gains from Investment Securities over the past 4 years was -$568500.0 (2021), compared with a mean of $203.4 million.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 266.76% in 2021 and later surged 271232.38% in 2022.
  • Avalo Therapeutics' Gains from Investment Securities stood at -$627000.0 in 2021, then surged by 271232.38% to $1.7 billion in 2022, then plummeted by 100.29% to -$5.0 million in 2024, then skyrocketed by 89.8% to -$510000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were -$510000.0 (Q4 2025), -$5.0 million (Q4 2024), and -$36.0 million (Q3 2024) per Business Quant data.